Recent discovery and development of AXL inhibitors as antitumor agents
Article in European Journal of Medicinal Chemistry (May 2024)
The most recent citing publications are shown below. View all 14 publications that cite this research output on Dimensions.
Ningetinib plus gefitinib in EGFR-mutant non-small-cell lung cancer with MET and AXL dysregulations: A phase 1b clinical trial and biomarker analysis
Article in Lung Cancer (January 2024)
Discovery of a 1,6-naphthyridin-4-one-based AXL inhibitor with improved pharmacokinetics and enhanced in vivo antitumor efficacy
Article in European Journal of Medicinal Chemistry (December 2023)